公开(公告)号：US09821017B2

公开(公告)日：2017-11-21

申请号：US14665538

申请日：2015-03-23

Applicant: JIN XIN BIOTECHNOLOGY CO., LTD. ,  ACADEMIA SINICA

Inventor： Kun-Hsuan Huang ,  Tza-Zen Chaung ,  Pei-Wen Hsiao ,  Chia-Jui Tsai

IPC: A61K36/11 ,  A61K36/185 ,  A61K36/12 ,  A61K31/231 ,  A61K31/232 ,  A61K31/409 ,  A61K31/23 ,  A23L33/105

CPC classification number: A61K36/12 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/23 ,  A61K31/231 ,  A61K31/232 ,  A61K31/409 ,  A23V2200/30

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

公开(公告)号：US09144591B2

公开(公告)日：2015-09-29

申请号：US14055545

申请日：2013-10-16

Applicant: Academia Sinica

Inventor： Pei-Wen Hsiao

IPC: A61K36/28

CPC classification number: A61K36/28

Abstract: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of IκB kinase subunit α activity. The composition can also be administered to a subject at high risk for prostate cancer as a method for reducing the subject's risk thereof. A further method relates to identifying a modulator of transcriptional activity regulated by IκB kinase subunit α. Still another method relates to determining the IκB kinase subunit α-regulated transcriptional activity regulated by in a non-human mammalian test subject.

Abstract translation: 本文公开了通过向受试者施用含有有效量的I＆kgr B激酶亚基α活性抑制剂的组合物来治疗有需要的受试者中的雄激素刺激的疾病的方法。 该组合物也可以作为降低受试者风险的方法施用于患有前列腺癌的高风险的受试者。 另一种方法涉及鉴定由I＆kgr; B激酶亚基α调节的转录活性的调节剂。 另一种方法涉及确定由非人哺乳动物测试受试者调节的I激酶亚基α调节的转录活性。

公开(公告)号：US20150265697A1

公开(公告)日：2015-09-24

申请号：US14619693

申请日：2015-02-11

Applicant: Academia Sinica

Inventor： Pei-Wen Hsiao ,  Chia-Ying Wu ,  Yi-Chun Yeh

IPC: A61K39/145 ,  C07K16/10 ,  G01N33/569

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/215 ,  A61K2039/5258 ,  C07K14/005 ,  C07K16/1018 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2830/006 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10 ,  G01N2469/20

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

Abstract translation: 从Vero细胞重组产生哺乳动物宿主病毒（如SARS-CoV和流感病毒）的病毒样颗粒（VLP）。 VLP密切模仿真实病毒颗粒的外观，具有高度的免疫原性。 它们可以引起哺乳动物体液，但也可引起细胞免疫反应。 还描述了与VLP相关的组合物和方法。

公开(公告)号：US09056077B2

公开(公告)日：2015-06-16

申请号：US13929444

申请日：2013-06-27

Applicant: JIN XIN BIOTECHNOLOGY CO., LTD. ,  ACADEMIA SINICA

Inventor： Kun-Hsuan Huang ,  Tza-Zen Chaung ,  Pei-Wen Hsiao ,  Chia-Jui Tsai

IPC: A61K36/11 ,  A61K36/185 ,  A61K36/12 ,  A61K31/231 ,  A61K31/232 ,  A61K31/409 ,  A61K31/23 ,  A23L1/30

CPC classification number: A61K36/12 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/23 ,  A61K31/231 ,  A61K31/232 ,  A61K31/409 ,  A23V2200/30

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract translation: of藜提取物包括焦脱镁叶酸甲酯（C34H36N4O3），偏硼酸甲酯（C35H36N4O5），1-亚麻酰-3-亚油酸 - 甘油（C39H66O5），1-亚麻酰基-2,3-二棕榈酰基 - 外消旋甘油 （C53H98O6）和1,3-二棕榈酰基-sn-甘油（C35H68O5）。 通过使用以下方法获得of The提取物，该方法包括以下步骤：溶剂萃取，使用溶剂萃取an an L. L. L. L. L. and and and and L L L L L L L L L L L L L 样品为50〜60mg / ml; 和柱色谱法，用水和乙醇作为洗脱液将提取物分馏，得到几种级分，包括级分a至级分i，并进一步蒸发和冻干级分b，c，d或其组合，得到As an提取物。

公开(公告)号：US10391163B2

公开(公告)日：2019-08-27

申请号：US15756774

申请日：2016-09-09

Applicant: Academia Sinica

Inventor： Shu-Mei Liang ,  Pei-Wen Hsiao ,  Ming-Chu Cheng ,  Yu-Chih Yang

IPC: A61K39/145 ,  C12N7/00 ,  A61K39/12 ,  A61K39/135 ,  A61K39/00 ,  A61P31/16

Abstract: A vaccine composition is disclosed. The vaccine composition comprises: (a) a therapeutically effective amount of an influenza virus-like particle (VLP) comprising: (i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; (b) Foot-and-mouth disease virus (FMDV) capsid protein VP3, recombinant FMDV VP3 (rVP3), VP3 peptide, or SUMO VP3; and (c) alum. Also disclosed is use of a vaccine composition according to the invention in the manufacture of a medicament for inducing an immunogenic response in a subject in need thereof.

公开(公告)号：US09795666B2

公开(公告)日：2017-10-24

申请号：US14619693

申请日：2015-02-11

Applicant: Academia Sinica

Inventor： Pei-Wen Hsiao ,  Chia-Ying Wu ,  Yi-Chun Yeh

IPC: A61K39/145 ,  C12N7/01 ,  A61P31/16 ,  A61K39/42 ,  C12N15/44 ,  A61K39/215 ,  C07K14/005 ,  A61K39/12 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/215 ,  A61K2039/5258 ,  C07K14/005 ,  C07K16/1018 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2830/006 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10 ,  G01N2469/20

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

公开(公告)号：US20150190441A1

公开(公告)日：2015-07-09

申请号：US14665538

申请日：2015-03-23

Applicant: JIN XIN BIOTECHNOLOGY CO., LTD. ,  ACADEMIA SINICA

Inventor： Kun-Hsuan Huang ,  Tza-Zen Chaung ,  Pei-Wen Hsiao ,  Chia-Jui Tsai

IPC: A61K36/12 ,  A61K31/23 ,  A61K31/231 ,  A61K31/409 ,  A61K31/232

CPC classification number: A61K36/12 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/23 ,  A61K31/231 ,  A61K31/232 ,  A61K31/409 ,  A23V2200/30

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract translation: of藜提取物包括焦脱镁叶酸甲酯（C34H36N4O3），偏硼酸甲酯（C35H36N4O5），1-亚麻酰-3-亚油酸 - 甘油（C39H66O5），1-亚麻酰基-2,3-二棕榈酰基 - 外消旋甘油 （C53H98O6）和1,3-二棕榈酰基-sn-甘油（C35H68O5）。 通过使用以下方法获得of The提取物，该方法包括以下步骤：溶剂萃取，使用溶剂萃取an an L. L. L. L. L. and and and and L L L L L L L L L L L L L 样品为50〜60mg / ml; 和柱色谱法，用水和乙醇作为洗脱液将提取物分馏，得到几种级分，包括级分a至级分i，并进一步蒸发和冻干级分b，c，d或其组合，得到As an提取物。

公开(公告)号：US20140141109A1

公开(公告)日：2014-05-22

申请号：US14055545

申请日：2013-10-16

Applicant: ACADEMIA SINICA

Inventor： Pei-Wen Hsiao

IPC: A61K36/28

CPC classification number: A61K36/28

Abstract: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of IκB kinase subunit α activity. The composition can also be administered to a subject at high risk for prostate cancer as a method for reducing the subject's risk thereof. A further method relates to identifying a modulator of transcriptional activity regulated by IκB kinase subunit α. Still another method relates to determining the IκB kinase subunit α-regulated transcriptional activity regulated by in a non-human mammalian test subject.

Abstract translation: 本文公开了通过向受试者施用含有有效量的I＆kgr B激酶亚基α活性抑制剂的组合物来治疗有需要的受试者中的雄激素刺激的疾病的方法。 该组合物也可以作为降低受试者风险的方法施用于患有前列腺癌的高风险的受试者。 另一种方法涉及鉴定由I＆kgr; B激酶亚基α调节的转录活性的调节剂。 另一种方法涉及确定由非人哺乳动物测试受试者调节的I激酶亚基α调节的转录活性。